Across TCGA pan-cancer cohorts, RPS26P20 RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated RPS26P20 data layer.

The strongest signal is observed in sarcoma (SARC), where higher RPS26P20 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RPS26P20 expression acts as an unfavorable survival marker, although some lineages such as MESO and CHOL show a favorable association.

SARC, MESO, and PAAD are the cancer types where RPS26P20 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	OS	Median	All	0.760	0.912	<.001	32	view →
MESO	DFS	Median	II,III,IV	0.726	0.174	<.001	30	view →
PAAD	OS	Tertile	All	0.240	0.544	<.001	29	view →
CHOL	OS	Median	All	0.838	0.352	<.001	28	view →
ACC	DFS	Quartile	II,III,IV	0.263	0.663	.010	22	view →
LUSC	DFS	Median	II,III,IV	0.677	0.504	.007	16	view →
CESC	DFS	Median	II,III,IV	0.806	0.602	.008	16	view →
KICH	DFS	Quartile	II,III,IV	0.721	1.000	.027	12	view →
KIRC	DFS	Median	IV	0.763	0.480	.008	10	view →
UCEC	DFS	Quartile	All	0.860	0.930	.011	10	view →
ESCA	DFS	Tertile	All	0.429	0.637	.011	10	view →
THYM	DFS	Quartile	III,IV	0.593	0.932	.003	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

Exploration

Same gene, other analysis: RPS26P20 tumor-vs-normal RNA expression · all RPS26P20 data types